Regenxbio Inc
RGNXHealthcare|Biotechnology|USA
$13.95
-1.71 (-10.92%)
Tangible Book
$0.41
About
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Stock Price
+54.0%(1Y)
Pipeline Summary
23 total trials4
Phase 1
10
Phase 2
5
Phase 3
0
Phase 4
ENROLLING_BY_INVITATION: 2Active: 6Completed: 4Withdrawn: 3Recruiting: 3Unknown: 2TEMPORARILY_NOT_AVAILABLE: 1SUSPENDED: 1Terminated: 1
Active Trials (9)
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
NCT07236606MPS II
Phase 3Active
Enrollment: 2 participants
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550Diabetic Retinopathy (DR)
Phase 2Active
Enrollment: 139 participants
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD
Phase 3Recruiting
Enrollment: 714 participants
CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
NCT03566043Mucopolysaccharidosis Type II (MPS II)
Phase 2Phase 3Active
Enrollment: 48 participants
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921AMD
Phase 2Phase 3Active
Enrollment: 671 participants
BioScore
4.2/10
Cautious
Ownership
Recent Insider Trades
PAKOLA STEVESELL
2026-07-022,161 shares @ $13.64
PAKOLA STEVESELL
2026-07-0156,333 shares @ $12.23
PAKOLA STEVESELL
2026-05-1115,309 shares @ $11.02
PAKOLA STEVESELL
2026-03-105,124 shares @ $10.35
Simpson CurranSELL
2025-10-0920,811 shares @ $12.62
Recent News
2026-06-29 12:00:07
2026-06-24 17:36:25
2026-06-24 12:00:05
2026-06-24 11:28:48
2026-06-22 18:36:28
Data last updated: Jul 12, 2026, 07:39 PM